Nika Pharmaceuticals, Inc (NIKA) stock
Close on Oct 16, 2026Market cap $431.19MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $431.19M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$78.14K
- EPS, diluted
- $0.00
- Book value per share
- -$0.00
- Diluted shares
- 1.05B
Trading
- Previous close
- $0.41
- Open
- $0.41
- Day's range
- $0.41 – $0.41
- Volume
- 0
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | NIKA | S&P 500 | Difference | NIKA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +1.5% | −1.5 pts | ||
| 3 months | -46.7% | +1.9% | −48.6 pts | ||
| Year to date | +7.9% | +12.8% | −4.9 pts | ||
| 1 year | -14.4% | +16.8% | −31.2 pts |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
About Nika Pharmaceuticals
Pharmaceutical Preparations
Nika Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing, and distributing prescription therapies and dietary food supplements. Its primary pharmaceutical assets include Thymus Nuclear Glycoprotein, intended for treating human immunodeficiency virus infections, alongside treatments developed on an inactivated pepsin fraction platform. The company also distributes multiple dietary supplement lines, including Carotilen, Physiolong, Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron, designed for cellular protection, immune stimulation, and physical convalescence. Its offerings serve individuals undergoing physical recovery as well as patients managing chronic viral conditions.
Company profile, executives and historyNika Pharmaceuticals stock: common questions
What is Nika Pharmaceuticals's stock price?
NIKA closed at $0.41 on Oct 16, 2026, up 0.00% on the day.
What is Nika Pharmaceuticals's market cap?
Nika Pharmaceuticals was worth $431.19M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.
What is NIKA's P/E ratio?
Nika Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
Does Nika Pharmaceuticals pay a dividend?
No. Nika Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has NIKA stock performed over the past year?
Including dividends, NIKA returned -14.4% over the past year, against +16.8% for the S&P 500.
Who are Nika Pharmaceuticals's competitors?
Companies most similar to Nika Pharmaceuticals by business, industry and size include BDPT, JAGX, ANIP, KMDA, GRFS.
See a number that looks wrong?